Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Unike, Houken Develop Generics Use Promotion Report System
September 14, 2009
- Janssen Enhances CNS Field with 370 MRs
September 14, 2009
- Pharmacists Should Be Allowed to Change Specifications/Dosage Forms at Their Own Discretion
September 14, 2009
- China's Essential Drug List May Hit Non-Chinese Drug Firms Operating in China
September 14, 2009
- JPA Member Pharmacies Continue to Sell OTC Drugs by Phone: Kenko.com
September 14, 2009
- Yano Research Predicts 6-9% NHI Price Cuts in April 2010
September 14, 2009
- Need for Importing New-Type Flu Vaccines Questioned
September 14, 2009
- Blopress Ranked as Best-Selling Drug in Japan in 1st Qtr: IMS Japan
September 14, 2009
- Healthcare Providers to Be Preferentially Vaccinated against New-Type Flu
September 14, 2009
- Market for RA Drugs to Expand to ¥195 Bil. in 2016: Fuji-Keizai
September 14, 2009
- National Healthcare Expenditure Reaches Highest-Ever ¥34,136 Bil. in FY2007
September 14, 2009
- Drug Sales & Marketing System Needs "Systematic Throwback": Mr Kadonaga
September 14, 2009
- Survey Shows Large Regional Gaps in Respiratory Medical Services
September 14, 2009
- BUSINESS NEWS IN BRIEF
September 14, 2009
- Nearly 70% of Local Gov't-Managed Hospitals Operate in the Red
September 14, 2009
- Novartis Ranked No. 1 in Oncology: Cancer Patient Survey
September 14, 2009
- PIII Study of Idebenone Initiated for DMD: Takeda
September 14, 2009
- Novartis Prepares Trial for New-Type Flu Vaccine with Adjuvant
September 14, 2009
- Ono Licenses Asimadoline from Tioga
September 14, 2009
- R&D NEWS IN BRIEF
September 14, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…